SciSparc: Subsidiary NeuroThera Labs Received Conditional Regulatory Approval for Acquisition of CliniQuantum
Stocks in this Quantisnow insightHealth Care
Historical context for SPRC
Across the 13 sessions after earlier SPRC headlines, the stock closed higher 4 times and lower 9 times, with a median move of 7.9% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | SPRC | SPY |
|---|---|---|---|
| Mar 16, 2026 | SciSparc: NeuroThera Labs- Clearmind Medicine Collaboration Leads to Patent Application for Depression Therapy | -0.9% | +1.0% |
| Mar 12, 2026 | SciSparc: NeuroThera Labs Announces Publication of International Patent in Collaboration with Clearmind Medicine for Novel Therapy Targeting Weight Loss and Fatty Liver Disease | +22.9% | -1.5% |
| Mar 10, 2026 | SciSparc: Subsidiary NeuroThera Labs (75%) Signs Definitive Agreement to Acquire Majority Stake in CliniQuantum, Innovator in Quantum-based Clinical trails | -28.3% | -0.2% |
| Mar 2, 2026 | SciSparc Announces 1-for-9 Reverse Share Split | -9.9% | +0.1% |
| Feb 2, 2026 | SciSparc: NeuroThera Labs Granted U.S. Patent for Cannabinoid Technology to Overcome Antimicrobial Resistance such as MRSA | +0.1% | +0.5% |
| Jan 26, 2026 | SciSparc Successfully Completes Acquisition of IP Portfolio, Advances Toward Immediate Commercialization | -7.9% | +0.5% |
Quantisnow market dataNASDAQ
SPRC
SciSparc Ltd.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
Get push alerts for SPRC
Full SPRC profile on Quantisnow Follow SPRC and get a push notification the moment its next story breaks.